#Herceptin

This treatment represents a “fairly substantial breakthrough” for patients with HER2-positive advanced colorectal cancer.

60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.

New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.

The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.

Removal of the primary breast tumor may be warranted in women who respond well to targeted therapies.

Black women, as well as those with Medicaid or no insurance, were less likely to receive surgery and more likely to die.

Kadcyla reduces the risk of breast cancer recurring and spreading after surgery.

HannaH trial demonstrated that Herceptin Hylecta was comparable to intravenous trastuzumab.

Experts say Kadcyla should become a new standard of care for adjuvant therapy.

Precision medicine matches patients with the treatments most likely to work for them.

Study shows six months of trastuzumab works as well as a full year.

World’s largest breast cancer conference celebrates 40 years.

Breast cancer recurrence and death among women who underwent breast-sparing surgery have decreased since the mid-1990s.